🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ankara
Clinical trial register · Turkey

Clinical Trials in Ankara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5432 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5432
Studies in scope
all four open statuses
2496
Recruiting now
open to new participants
552
Lead sponsors
across recruiting studies
Top sites
Istanbul 2009 Ankara 1457 Izmir 568 Adana 378 Antalya 259
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hacettepe University132 AstraZeneca102 Merck Sharp & Dohme LLC91 Ankara City Hospital Bilkent73 Ankara Etlik City Hospital64
Site location
Istanbul2009 Ankara1457 Izmir568 Adana378 Antalya259
All 319 locations
Target enrolment
to

Trials with a site in Ankara

1457 of 5432 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Active, closed
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110Lung Malignancy
AstraZeneca
Observational
712
Ankara, Mersin
2023-04-20
Active, closed
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252Non-small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab
Klus Pharma Inc.
Phase 2
356
Adana, Ankara
2023-04-19
Active, closed
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931Endometrial Cancer
DrugSelinexor
Karyopharm Therapeutics Inc
Phase 3
257
Çankaya, Adana, Ankara, Istanbul
2023-04-18
Active, closed
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843Primary Biliary Cholangitis (PBC)
Umecrine Cognition AB
Phase 1/2
84
Ankara, Balçova, Diyarbakır, Izmir, Kocaeli, Rize, Sanliurfa, Trabzon
2023-04-14
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
DrugsTobemstomig·Tiragolumab·Atezolizumab
Hoffmann-La Roche
Phase 2
204
Adana, Ankara, Edirne, Izmir, Kadiköy
2023-04-13
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Afyonkarahisar, Ankara, Antalya, Istanbul, Izmir, Kayseri, Mersin, Samsun
2023-04-11
Active, closed
The Study, Conducted With 54 Individuals Over the Age of 65, Aimed to Reveal the Advantages and Disadvantages of a Combined Exercise Program Compared to Otago Exercise Alone.
NCT07689903Sarcopenia in Elderly
Hacettepe University
Not applicable
54
Ankara
2023-04-01
Recruiting
Photobiomodulation in Dry Age Related Macular Degeneration
NCT06046118Age-Related Macular Degeneration
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Not applicable
180
Ankara, Koç
2023-04-01
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Ankara, Aydin, Bursa, Dinar, Istanbul, Izmir, Samsun
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Ankara, Antalya, Denizli, Istanbul, Samsun
2023-03-29
Recruiting
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
NCT05767047Behçet's Disease, Juvenile Psoriatic Arthritis
DrugApremilast
Amgen
Phase 3
48
Ankara, Istanbul
2023-03-23
Active, closed
İnvestigating Dysphagia in Pediatric Dystonia
NCT06815757Dystonia Disorder
Gazi University
Observational
25
Ankara
2023-03-17
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Adana, Ankara, Atakum, Diyarbakır, Konya, Meram Konya, Yenimahalle
2023-03-16
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
Ankara, Eskişehir, Istanbul
2023-03-16
Active, closed
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Riabni·Ruxience·Truxima
Merck Sharp & Dohme LLC
Phase 3
300
Stanbul, Suleymanpasa, Ankara, Istanbul, Izmir
2023-03-16
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Adana, Ankara
2023-03-15
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Izmir, Ankara, Istanbul, Denizli, Kayseri, Muğla, Eskişehir, Gaziantep
2023-03-09
Active, closed
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
NCT05705349HIV-1 Infection
DrugsDOR/ISL·B/F/TAF
Merck Sharp & Dohme LLC
Phase 3
537
Altindağ, Ankara
2023-03-08
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
DrugsVepdegestrant·Fulvestrant
Pfizer
Phase 3
624
Altindağ, Istanbul, Izmir, Adana, Ankara, Antalya, Edirne, Samsun
2023-03-03
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
436
Ankara, Istanbul
2023-03-02
Active, closed
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT05669755Cardiovascular Disease
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
7,101
Ankara, Istanbul, Eskişehir, Bursa, Adana, Afyonkarahisar, Edirne, Izmir
2023-03-01
Active, closed
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
NCT05933200Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Ultragenyx Pharmaceutical Inc
Phase 3
69
Adana, Ankara, Bornova-İzmir, Istanbul
2023-02-28
Recruiting
Weight Loss and CLOCK 3111T/C Polymorphism
NCT05750732Polymorphism, Restriction Fragment Length, Obesity
Hacettepe University
Observational
400
Ankara
2023-02-20
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Ankara, Bursa, Diyarbakır, Elâzığ, Erciyes, Istanbul, Izmir, Konya
2023-02-15
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Ankara, Istanbul, Izmir, Kayseri, Malatya
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Ankara, Capa-ISTANBUL, Antalya, Adana, Bornova-IZMIR, Edirne
2023-02-13
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
195
Istanbul, Adana, Ankara, Izmir
2023-02-10
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Ankara, Dilovası, Samsun, Trabzon, Malatya, Yüreğir
2023-02-08
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Ankara, Edirne, Istanbul, Izmir, Mersin
2023-02-06
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Samsun, Ankara, Aydin, Istanbul, Izmir
2023-02-02
Active, closed
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
DrugDexpramipexole Dihydrochloride
Areteia Therapeutics
Phase 3
600
Adana, Ankara, Antalya, Bornova, Center, Istanbul, Konak, Mersin
2023-01-30
Active, closed
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220Breast Cancer, Metastatic Breast Cancer
DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus
Stemline Therapeutics, Inc.
Phase 1/2
435
Ankara
2023-01-24
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
42
Ankara, Istanbul
2023-01-19
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Ankara, Antalya, Istanbul, Kocaeli, Malatya
2023-01-16
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,564
Yüreğir, Sur, İzmit, Gaziantep, Ankara, Edirne, Istanbul
2023-01-16
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Ankara, Istanbul, Kocaeli
2023-01-12
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712Sickle Cell Disease
DrugEtavopivat
Forma Therapeutics, Inc.
Phase 2
95
Ankara, Seyhan
2023-01-12
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
Ankara, Antalya, Gaziantep
2023-01-12
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Pemetrexed·Keytruda·Cisplatin
Daiichi Sankyo
Phase 3
1,170
Ankara, Antalya, Bağcılar, Bornova-Izmir, Cankaya/Ankara, Etimesgut Ankara, Istanbul, Seyhan
2023-01-11
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Kocaeli, Ankara, Rize
2023-01-02
Active, closed
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673Non-Clear Cell Renal Cell Carcinoma
DrugsSunitinib Malate·Zanzalintinib·Sunitinib·Opdivo
Exelixis
Phase 3
317
Adana, Ankara, Istanbul, Izmir
2023-01-01
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab deruxtecan·Durvalumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 3
1,350
Adana, Ankara, Edirne, Istanbul, Izmir
2022-12-29
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
Ankara, Istanbul
2022-12-28
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
DrugAbelacimab
Anthos Therapeutics, Inc.
Phase 3
2,500
Adana, Istanbul, Pendik, Izmir, Ankara, Antalya, Bursa, Diyarbakır
2022-12-27
Active, closed
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
DrugsTafasitamab·Lenalidomide
Incyte Corporation
Phase 3
82
Ankara, Center, Istanbul, Izmir, Kayseri, Mersin, Yenimahalle
2022-12-23
Recruiting
Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study
NCT05950750TTP - Thrombotic Thrombocytopenic Purpura
Turkish Hematology Association
Observational
960
Ankara
2022-12-21
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Ankara, Diyarbakır, Istanbul, Izmir, İzmit, Malatya, Ortahisar
2022-12-13
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
DrugsCapmatinib·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
57
Ankara, Çankaya
2022-12-13
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
Ankara, Edirne, Istanbul, Kadıköy, Konya
2022-12-13
Active, closed
Comparison of Bulk-Fill Composite Resins in Class II Restorations
NCT06212141Class II Dental Caries
Hacettepe University
Not applicable
54
Ankara
2022-12-12
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
DrugMarstacimab
Pfizer
Phase 3
100
Istanbul, Melikgazi, Adana, Ankara, Izmir, Kayseri, Samsun
2022-12-09
Active, closed
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
DrugJDQ443
Novartis Pharmaceuticals
Phase 2
95
Istanbul, Diyarbakır, Ankara
2022-12-06
Active, closed
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
NCT04705389Merkel Cell Carcinoma
University Hospital, Tours
Not applicable
35
Ankara
2022-12-05
By invitation
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
NCT05492799MPS III B
Allievex Corporation
Phase 4
15
Ankara
2022-12-02
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
DrugsABL001·Asciminib·Nilotinib
Novartis Pharmaceuticals
Phase 3
568
Istanbul, Ankara, Izmir
2022-11-21
Recruiting
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
NCT06465433Hematologic Malignancies
DrugTafasitamab
Incyte Corporation
Phase 2
25
Ankara
2022-11-08
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
DrugFinerenone
Bayer
Phase 3
100
Adana, Ankara, Istanbul
2022-11-08
Active, closed
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
3,400
Ankara, Sultangazi, Adana, Antalya, Hatay, Istanbul, Sivas
2022-11-01
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Ankara, Antalya, Denizli, Istanbul, Izmir, Samsun
2022-10-25
Recruiting
The CATALINA Study
NCT05008081Chronic Obstructive Pulmonary Disease Exacerbation
Wim Janssens
Observational
1,000
Ankara
2022-10-25
Active, closed
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378Lung Cancer, Non-Small Cell
DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 2
351
Samsun, Ankara, Antalya, Istanbul
2022-10-14
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Ankara, Antalya, Istanbul, Izmir, Samsun
2022-10-13
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Ankara, Edirne, Fatih, Istanbul, Kaakaekmece, Malatya
2022-10-12
Recruiting
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
NCT05491525Neurogenic Detrusor Overactivity
DrugVibegron
Urovant Sciences GmbH
Phase 2/3
71
Ankara, Yenişehir
2022-10-12
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Adana, Ankara, Antalya, Aydin, Balçova, Bornova, Denizli, Gaziantep
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Adana, Adapazarı, Altindağ, Ankara, Antalya, Bursa, Diyarbakır, Edirne
2022-10-04
Recruiting
Exercise Program for Patients With Cervical Dystonia Who Are Treated With Botulinum Toxin Type A
NCT05502718Dystonia, Cervical
Prof. Dr. Şehim Kutlay
Not applicable
34
Ankara
2022-10-01
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Ankara, Istanbul, Izmir, Mersin
2022-09-27
Recruiting
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
NCT03083431Retinopathy of Prematurity
DrugPropranolol
University of Zurich
Phase 2
276
Ankara
2022-09-22
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib
Celgene
Phase 3
810
Ankara, Istanbul, Izmir, Kayseri, Samsun
2022-09-20
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
DrugsEpcoritamab·Lenalidomide·Rituximab
Genmab
Phase 3
549
Ankara, Antalya, Diyarbakır, Istanbul, Izmir, Kocaeli, Samsun
2022-09-20
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Ankara, Istanbul, Izmir, Kayseri
2022-09-08
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Datopotamab deruxtecan
AstraZeneca
Phase 2
454
Ankara, Cordaleo, Edirne, Kadıkoy/Istanbul, Konya, Pamukkale, Samsun
2022-09-06
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Ankara, Tevikiye
2022-09-05
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
Adana, Ankara, Bornova, Istanbul
2022-08-31
By invitation
Central Neuromuscular Dysfunction in Patellofemoral Pain
NCT05561153Patellofemoral Pain Syndrome
Hacettepe University
Observational
40
Ankara
2022-08-15
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Ankara, Istanbul, Kayseri, Bursa, Mersin
2022-08-10
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
Adana, Ankara, Edirne, Istanbul, Izmir, Samsun
2022-08-05
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
341
Adana, Ankara, Edirne, Istanbul, Izmir
2022-08-03
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus
Genentech, Inc.
Phase 3
373
Ankara, Sakarya
2022-08-03
Recruiting
Tactile/kinesthetic Stimulus Program
NCT05486663Breast Feeding, Exclusive, Enteral Feeding, Hospital Stay
Gonca Karatas Baran
Not applicable
80
Ankara
2022-08-01
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Taxol·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Adana, Ankara, Edirne, Istanbul, Izmir, Sariyer, Şişli
2022-07-25
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Ankara, Balçova, Bornova, Faith, Istanbul, Mamak
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Stanbul, Bornova, Ankara, Edirne, Samsun
2022-07-21
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Adana, Ankara, Edirne, Istanbul, Izmir, Sariyer
2022-07-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsPhesgo·Giredestrant·Docetaxel·Paclitaxel
Hoffmann-La Roche
Phase 3
922
Adana, Ankara, Diyarbakır, Edirne, Erzurum, Istanbul, Izmir, İzmit
2022-07-18
Recruiting
Otoferlin Gene-mediated Hearing Loss Natural History Study
NCT05572073Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Observational
150
Ankara
2022-07-14
Active, closed
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672Melanoma
DrugsFianlimab·Cemiplimab·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,546
Yüreğir, Istanbul, Izmir, İzmit, Gaziantep, Ankara, Diyarbakır, Edirne
2022-07-14
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
NCT05406401Lymphoma, Large B-Cell, Diffuse (DLBCL)
DrugsRituximab Biosimilar·Zilovertamab vedotin·Truxima·Cytoxan
Merck Sharp & Dohme LLC
Phase 2
60
Stanbul, Ankara, Edirne
2022-07-14
Active, closed
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT05426733Biliary Atresia
DrugOdevixibat
Albireo, an Ipsen Company
Phase 3
180
Ankara, Antalya, Istanbul
2022-07-05
Recruiting
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
NCT05430971Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Immune Oncology Research Institute
Observational
200
Ankara, Istanbul
2022-07-01
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Kavaklıdere, Yenimahalle, Pendik, Balçova, Bornova, Samsun, Ankara, Gaziantep
2022-06-23
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab
Sanofi
Phase 3
531
Ankara, Istanbul, Izmir
2022-06-23
Active, closed
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
NCT05181618Severe Hemophilia A, Moderate Hemophilia A
DrugEmicizumab
Hoffmann-La Roche
Phase 4
136
Ankara, Antalya, Istanbul, Izmir
2022-06-20
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib
BioNTech SE
Phase 1
320
Adana, Ankara, Istanbul, Izmir
2022-06-17
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
DrugsJDQ443·Docetaxel
Novartis Pharmaceuticals
Phase 3
95
Adana, Ankara, Istanbul
2022-06-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
NCT05144256Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
49
Izmir, Ankara, Istanbul
2022-06-08
Active, closed
THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05208944Carcinoma, Non-Small-Cell Lung
DrugsThiotepa·Cemiplimab
Maia Biotechnology
Phase 2
227
Ankara, Istanbul
2022-06-08
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Ankara, Antalya, Bursa, Edirne, Erciyes, Istanbul, Kocaeli
2022-05-30
Recruiting
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
NCT05487612Coronary Artery Disease, Aortic Valve Stenosis, Extracorporeal Circulation; Complications
Aristotle University Of Thessaloniki
Not applicable
1,300
Ankara, Izmir, Rize
2022-05-26
Rows per page Showing 1101–1200 of 1457
Previous 10 11 12 13 14 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-turkey/city/ankara?page=12

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,432 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,457 of those studies with a site in Ankara.

How many clinical trials are recruiting in Ankara?

706 of the 1,457 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 176 have not yet opened recruitment, 513 are active but closed to new participants, and 62 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.